Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HH160
- Development stage
- Phase 1
- Lead developer
- Huahui Health
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HH160 is an investigational trispecific antibody being developed by Huahui Health (Beijing Huahui Health Biotech) for the treatment of solid tumors. As a trispecific antibody, HH160 is engineered to simultaneously bind three different antigens or epitopes. This modality is typically designed to enhance anti-tumor activity by bridging tumor cells with immune effector cells (such as T cells or NK cells) while potentially incorporating a third binding site for costimulation or checkpoint inhibition to overcome the immunosuppressive tumor microenvironment. The drug is currently in the early stages of development within Huahui Health's oncology pipeline.
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on HH160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH160.